Cargando…

CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model

Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time the effect of the anti-CK2 CIGB-300 peptide in NCI-H460 cells as an LCLC model. NCI-H460 cells were highly sen...

Descripción completa

Detalles Bibliográficos
Autores principales: Pérez, George V., Rosales, Mauro, Ramón, Ailyn C., Rodríguez-Ulloa, Arielis, Besada, Vladimir, González, Luis J., Aguilar, Daylen, Vázquez-Blomquist, Dania, Falcón, Viviana, Caballero, Evelin, Carvalho, Paulo C., Caldeira, Rodrigo Soares, Yang, Ke, Perera, Yasser, Perea, Silvio E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856093/
https://www.ncbi.nlm.nih.gov/pubmed/36672551
http://dx.doi.org/10.3390/biomedicines11010043
_version_ 1784873538479456256
author Pérez, George V.
Rosales, Mauro
Ramón, Ailyn C.
Rodríguez-Ulloa, Arielis
Besada, Vladimir
González, Luis J.
Aguilar, Daylen
Vázquez-Blomquist, Dania
Falcón, Viviana
Caballero, Evelin
Carvalho, Paulo C.
Caldeira, Rodrigo Soares
Yang, Ke
Perera, Yasser
Perea, Silvio E.
author_facet Pérez, George V.
Rosales, Mauro
Ramón, Ailyn C.
Rodríguez-Ulloa, Arielis
Besada, Vladimir
González, Luis J.
Aguilar, Daylen
Vázquez-Blomquist, Dania
Falcón, Viviana
Caballero, Evelin
Carvalho, Paulo C.
Caldeira, Rodrigo Soares
Yang, Ke
Perera, Yasser
Perea, Silvio E.
author_sort Pérez, George V.
collection PubMed
description Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time the effect of the anti-CK2 CIGB-300 peptide in NCI-H460 cells as an LCLC model. NCI-H460 cells were highly sensitive toward CIGB-300 cytotoxicity, reaching a peak of apoptosis at 6 h. Moreover, CIGB-300 slightly impaired the cell cycle of NCI-H460 cells. The CIGB-300 interactomics profile revealed in more than 300 proteins that many of them participated in biological processes relevant in cancer. Interrogation of the CK2 subunits targeting by CIGB-300 indicated the higher binding of the peptide to the CK2α′ catalytic subunit by in vivo pull-down assays plus immunoblotting analysis and confocal microscopy. The down-regulation of both phosphorylation and protein levels of the ribonuclear protein S6 (RPS6) was observed 48 h post treatment. Altogether, we have found that NCI-H460 cells are the most CIGB-300-sensitive solid tumor cell line described so far, and also, the findings we provide here uncover novel features linked to CK2 targeting by the CIGB-300 anticancer peptide.
format Online
Article
Text
id pubmed-9856093
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98560932023-01-21 CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model Pérez, George V. Rosales, Mauro Ramón, Ailyn C. Rodríguez-Ulloa, Arielis Besada, Vladimir González, Luis J. Aguilar, Daylen Vázquez-Blomquist, Dania Falcón, Viviana Caballero, Evelin Carvalho, Paulo C. Caldeira, Rodrigo Soares Yang, Ke Perera, Yasser Perea, Silvio E. Biomedicines Article Large cell lung carcinoma (LCLC) is one form of NSCLC that spreads more aggressively than some other forms, and it represents an unmet medical need. Here, we investigated for the first time the effect of the anti-CK2 CIGB-300 peptide in NCI-H460 cells as an LCLC model. NCI-H460 cells were highly sensitive toward CIGB-300 cytotoxicity, reaching a peak of apoptosis at 6 h. Moreover, CIGB-300 slightly impaired the cell cycle of NCI-H460 cells. The CIGB-300 interactomics profile revealed in more than 300 proteins that many of them participated in biological processes relevant in cancer. Interrogation of the CK2 subunits targeting by CIGB-300 indicated the higher binding of the peptide to the CK2α′ catalytic subunit by in vivo pull-down assays plus immunoblotting analysis and confocal microscopy. The down-regulation of both phosphorylation and protein levels of the ribonuclear protein S6 (RPS6) was observed 48 h post treatment. Altogether, we have found that NCI-H460 cells are the most CIGB-300-sensitive solid tumor cell line described so far, and also, the findings we provide here uncover novel features linked to CK2 targeting by the CIGB-300 anticancer peptide. MDPI 2022-12-25 /pmc/articles/PMC9856093/ /pubmed/36672551 http://dx.doi.org/10.3390/biomedicines11010043 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pérez, George V.
Rosales, Mauro
Ramón, Ailyn C.
Rodríguez-Ulloa, Arielis
Besada, Vladimir
González, Luis J.
Aguilar, Daylen
Vázquez-Blomquist, Dania
Falcón, Viviana
Caballero, Evelin
Carvalho, Paulo C.
Caldeira, Rodrigo Soares
Yang, Ke
Perera, Yasser
Perea, Silvio E.
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
title CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
title_full CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
title_fullStr CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
title_full_unstemmed CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
title_short CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
title_sort cigb-300 anticancer peptide differentially interacts with ck2 subunits and regulates specific signaling mediators in a highly sensitive large cell lung carcinoma cell model
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856093/
https://www.ncbi.nlm.nih.gov/pubmed/36672551
http://dx.doi.org/10.3390/biomedicines11010043
work_keys_str_mv AT perezgeorgev cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT rosalesmauro cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT ramonailync cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT rodriguezulloaarielis cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT besadavladimir cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT gonzalezluisj cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT aguilardaylen cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT vazquezblomquistdania cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT falconviviana cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT caballeroevelin cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT carvalhopauloc cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT caldeirarodrigosoares cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT yangke cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT pererayasser cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel
AT pereasilvioe cigb300anticancerpeptidedifferentiallyinteractswithck2subunitsandregulatesspecificsignalingmediatorsinahighlysensitivelargecelllungcarcinomacellmodel